DxTerity Diagnostics | GenomeWeb

DxTerity Diagnostics

The firm plans to seek Emergency Use Authorization for the 18-gene panel and will subsequently submit it to the FDA for full approval.

The firm will use the money from SWK Funding to commercialize its DxDirect genomic testing platform and its DxCollect MicroCollection Device.

The additional funds bring the total contract to $43 million over approximately eight years.

With eight independently programmable amplification wells, the firm's portable PCR platform is now in small-scale production.

Molecular diagnostics company DxTerity Diagnostics was recently awarded a $280,000 Small Business Innovation Research contract from the National Cancer Institute to develop a test for susceptibility to radiation sickness during cancer treatment.

DxTerity Diagnostics has developed a rapid assay for analyzing gene expression of as many as 100 genes directly from small amounts of formalin-fixed, paraffin-embedded clinical samples without prior RNA extraction.

DxTerity plans to make the gene expression assays functional with its Non-Enzymatic Amplification Technology platform.

The grants, awarded through the Qualifying Therapeutic Discovery Project Program created by the Patient Protection and Affordable Care Act of 2010, were disclosed last week by the IRS.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.